IRIS
Di Lorenzo, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 363
EU - Europa 59
NA - Nord America 52
Totale 474
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 276
HK - Hong Kong 87
IT - Italia 48
MX - Messico 36
CA - Canada 12
NL - Olanda 9
US - Stati Uniti d'America 4
GB - Regno Unito 2
Totale 474
Salva come PNG Salva come JPEG
Città #
Singapore 140
Hong Kong 74
Mexico City 36
Rome 27
Naples 10
Nepean 4
Vancouver 3
Abbotsford 2
Calvisano 2
Domicella 2
Hamilton 2
Oxford 2
Palermo 2
Venice 2
Amsterdam 1
Ashburn 1
Council Bluffs 1
Mesagne 1
Prineville 1
Salt Lake City 1
Totale 314
Salva come PNG Salva come JPEG
Nome #
Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients 16
Everolimus as second-line therapy for metastatic renal cell carcinoma: a 'real-life' study 7
Validation of Psychometric Tools for Assessing Fatigue, Mood, and Sleep Quality: Application in the PREVES-STOP Study. 6
A case of renal melanoma metastasis: Description of clinico-pathological features 6
Paclitaxel in Pretreated Metastatic Penile Cancer: Final Results of a Phase 2 Study 5
Prospective evaluation of entrainment mapping as an adjunct to new-generation high-density activation mapping systems of left atrial tachycardias 5
A comprehensive outlook on intracerebral therapy of malignant gliomas. 5
The Effect of Vaccination against COVID-19 in Cancer Patients: Final Results of the COICA Trial 4
Prostate Cancer Detection in the "Grey Area" of Prostate-Specific Antigen Below 10 ng/ml: Head-to-Head Comparison of the Updated PCPT Calculator and Chun's Nomogram, Two Risk Estimators Incorporating Prostate Cancer Antigen 3 4
A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy 4
The Impact of Flavonoid Supplementation on Serum Oxidative Stress Levels Measured via D-ROMs Test in the General Population: The PREVES-FLAVON Retrospective Observational Study 4
Re: Matthew R. Smith, Maha Hussain, Fred Saad, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022;386:1132–1142 4
Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers 4
Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results 4
Fisetin as an adjuvant treatment in prostate cancer patients receiving androgen-deprivation therapy 4
Novel Chemotherapy-Sparing Approach for HER2-Low, ER-Positive Breast Cancer: Combining Trastuzumab Deruxtecan with Endocrine Therapy 4
ADVERSE EVENTS 1 OF IMMUNE CHECKPOINT INHIBITORS THERAPYFOR UROLOGIC CANCER PATIENTS IN CLINICAL TRIALS: A COLLABORATIVE SYSTEMATIC REVIEW AND META ANALYSIS 4
Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer 4
Re: Silke Gillessen Sommer, Thomas Powles. Advice for Medical Oncology Care of Urological Cancer Patients During the COVID-19 Pandemic. Eur Urol 2020;78:e2–3: Is It Always Correct to Continue Androgen Receptor Signaling Inhibitors in the COVID-19 Era? 4
Re: Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study 4
Sipuleucel-T (Provenge®) for castration-resistant prostate cancer 4
Supplements in Oncology: Uses, Hurdles, Guidance, and Future Perspective. 4
A Retrospective Study of Cemiplimab Effectiveness in Elderly Patients with Squamous Cell Carcinoma of the Skin: Insights from a Real-Life Scenario 4
Antagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cells 4
Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: A phase II study 3
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis 3
Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study 3
Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer 3
Metabolomic profiling for the identification of novel diagnostic markers and therapeutic targets in prostate cancer: an update 3
Testicular cancer from diagnosis to epigenetic factors 3
Immunotherapy for the treatment of prostate cancer 3
Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor 3
Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients 3
Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: a systematic review and meta-analysis 3
Coronavirus disease (COVID-19) in Italy: Analysis of risk factors and proposed remedial measures 3
Adrenalectomy: defining its role in the surgical treatment of renal cell carcinoma. 3
Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma 3
Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi's sarcoma: A multicenter study 3
Nefrectomia citoriduttiva e palliativa 3
Imatinib mesylate in thymic epithelial malignancies 3
Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection 3
Authors' reply 3
Unraveling the Dietary Puzzle: Exploring the Influence of Diet, Nutraceuticals, and Supplements on Bladder Cancer Risk, Outcomes, and Immunotherapy Efficacy: Insights from the BLOSSOM Study and Beyond 3
Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor 3
Matrix metalloproteinase-2 and-9 in the urine of prostate cancer patients 3
Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) Significantly Improve Prostate Cancer Detection at Initial Biopsy in a Total PSA Range of 2-10 ng/ml 3
Soluble interleukin-6 receptor to interleukin-6 (sIL-6R/IL-6) ratio in serum as a predictor of high Gleason sum at radical prostatectomy 3
Concurrent Chemoradiotherapy for Men With Locally Advanced Penile Squamous Cell Carcinoma 3
Real-world experience with cabazitaxel in patients with metastatic castration-resistant prostate cancer: a final, pooled analysis of the compassionate use programme and early access programme 3
Techniques of iconographic documentation [Techniche di documentazione iconografica] 3
Incidence of fatigue and low dose of corticosteroids in patients receiving systemic treatment: a metanalysis of randomized trials 3
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: A phase II study 3
Clinical characteristics of metastatic prostate cancer patients infected with COVID-19 in South Italy 3
Outcomes associated with first-line PD-1 and PD-L1 inhibitors vs. sunitinib in patients with renal cell cancer with sarcomatoid features: a systematic review and meta-analysis 3
Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients 3
Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies 3
A Challenging Surgical Approach to Locally Advanced Primary Urethral Carcinoma: A Case Report and Literature Review 3
The Impact of Routine Molecular Screening for SARS-CoV-2 in Patients Receiving Anticancer Therapy: An Interim Analysis of the Observational COICA Study 3
A Prognostic Model for Patients With Metastatic Renal Cell Cancer: What's New? 3
Predictors of Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis 3
Association of prior local therapy and outcomes with PD(L)1 inhibitors in advanced urothelial cancer 3
Peg-filgrastim and cabazitaxel in prostate cancer patients 3
Interaction between electromagnetic waves and auditory organs 3
Synergistic Combination of Quercetin and Mafosfamide in the Treatment of Bladder Cancer Cells 3
Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis 3
Renal cell carcinoma guideline 3
Incidence of fatigue and low-dose corticosteroid use in prostate cancer patients receiving systemic treatment: a meta-analysis of randomized controlled trials 3
READY: REAl-world Data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma 3
A complete response with rituximab in metastatic diffuse large B-cell lymphoma of the testis: case report 3
Adrenal sparing surgery in the treatment of renal cell carcinoma: when is it possible? 3
Perioperative Immune Checkpoint Inhibitors in Renal Cell and Urothelial Carcinomas: An Exciting New Paradigm under Investigation? 3
Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial 3
Focus on localized laryngeal amyloidosis: Management of five cases 3
The role of immunotherapy in oncology 3
Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms 3
INCREASED EXPRESSION OF THE AUTOCRINE MOTILITY FACTOR IS ASSOCIATED WITH POOR PROGNOSIS IN PATIENTS WITH CLEAR CELL – RENAL CELL CARCINOMA 3
Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma 3
A long-lasting response to sorafenib treatment in an advanced hepatocellular carcinoma patient 3
Combination therapy for metastatic renal cell carcinoma 3
Is in vitro-acquired resistance to enzalutamide a useful model? 3
BAG3 protein delocalisation in prostate carcinoma 3
READY: Real-world data from an Italian compassionate use program of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC) 3
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma 3
An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples 3
Pegylated liposomal doxorubicin in stage IVB mycosis fungoides 3
Expression of HECA-452 antigen correlates with disease relapse in mycosis fungoides 3
The Role of Sipuleucel-T in Therapy for Castration-Resistant Prostate Cancer: A Critical Analysis of the Literature 3
Medical expulsive treatment of distal-ureteral stones using tamsulosin: A single-center experience 3
Effect of baseline characteristics on cabazitaxel treatment duration in patients with metastatic castration-resistant prostate cancer (mCRPC): a post hoc analysis of the compassionate use (CUP)/expanded access programs (EAP) and CAPRISTANA registry 3
Activity of platinum-based chemotherapy in advanced prostate cancer patients with and without DNA repair gene aberrations: An International Collaborative Analysis 3
Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin 3
Corrigendum to Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: The RAINBOW analysis [Ann Oncol 26, 2015 2107-2113] (doi: 10.1093/annonc/mdv315)] 2
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma 2
Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis 2
Bicalutamide-induced gynaecomastia: Do we have the answer? 2
Kaempferol, myricetin and fisetin in prostate and bladder cancer: A systematic review of the literature 2
Clinical Outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib 2
Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy: A Multicenter Experience 2
PCA3 COMPARISON WITH PROSTATE HEALTH INDEX (PHI) IN REPEAT BIOPSY PATIENTS 2
Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma 2
Totale 337
Salva come PNG Salva come JPEG
Categoria #
all - tutte 3.960
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.960
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/2025832 0 0 0 28 338 19 114 333 0 0 0 0
Totale 832